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Abstract
Background—Depression is a heritable trait that exists on a continuum of varying severity and
duration. Yet, the search for genetic variants associated with depression has had few successes.
We exploit the entire continuum of depression to find common variants for depressive symptoms.
Methods—In this genome-wide association study, we combined the results of 17 population-
based studies assessing depressive symptoms with the Center for Epidemiological Studies
Depression Scale. Replication of the independent top hits (p < 1 × 10−5) was performed in five
studies assessing depressive symptoms with other instruments. In addition, we performed a
combined meta-analysis of all 22 discovery and replication studies.
Results—The discovery sample comprised 34,549 individuals (mean age of 66.5) and no loci
reached genome-wide significance (lowest p = 1.05 × 10−7). Seven independent single nucleotide
polymorphisms were considered for replication. In the replication set (n = 16,709), we found
suggestive association of one single nucleotide polymorphism with depressive symptoms
(rs161645, 5q21, p = 9.19 × 10−3). This 5q21 region reached genome-wide significance (p = 4.78
× 10−8) in the overall meta-analysis combining discovery and replication studies (n = 51,258).
Conclusions—The results suggest that only a large sample comprising more than 50,000
subjects may be sufficiently powered to detect genes for depressive symptoms.
Keywords
Center for Epidemiologic Studies Depression Scale; CHARGE consortium; depression; depressive
symptoms; genetics; genome-wide association study; meta-analysis
Major depressive disorder (MDD) is a complex disease with an underlying heritable
component. Family and twin studies report a high familial tendency of the disorder and
heritability estimates of 31% to 42% (1,2). However, the long search for genetic variants
associated with depression has had few successes. Several linkage studies for major
depressive disorder have been performed and these identified only one relevant locus (3,4).
In addition, hundreds of candidate genes have been investigated in association studies, but
only six variants have been confirmed in meta-analyses (5,6). Recent efforts to find new
candidate genes via genome-wide association studies (GWAS) have also been largely
unsuccessful (7–15). Genome-wide association studies identified interesting regions, but
associations with MDD reached standard levels of genome-wide significance at only one
locus (15). Furthermore, only few previously reported candidate genes were replicated in
genome-wide association studies (7,13,16).
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Depression exists on a continuum of varying severity and duration. Depressive symptoms
(measured on a continuous scale) and MDD (measured on a dichotomous scale) are
associated with similar patterns of risk factors suggesting shared etiology with varying
severity (17). The ability to detect genetic predictors might, therefore, be improved by
analyzing depression quantitatively (18), defining MDD as a diagnostic entity applied to the
extreme of the depression continuum (19). Using the phenotypic variation within cases and
control subjects by analyzing depression quantitatively has been shown to greatly increase
the power to detect genetic variants (20). In fact, a GWAS of the depression facet of
personality (a continuous trait) identified several candidate genes. However, the sample size
was small and findings remain to be confirmed (21).
In the current study, we exploit the entire continuum of depression, defined as the number
and severity of depressive symptoms a person experiences. We assessed depressive
symptoms with one of the most widely used instruments in the general population, namely
the Center for Epidemiological Studies Depression (CES-D) scale. This scale assesses the
following major dimensions of depression: depressed mood, feelings of guilt and
worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of
appetite, and sleep disturbance. The CES-D detects cases of MDD with high sensitivity and
specificity (22) and has proven to be relatively stable over time (82% of older adults had
stable CES-D scores over four measurement rounds in 10 years) (23,24). In addition, a high
CES-D score, like a diagnosis of MDD, is associated with cardiovascular disease and
mortality (25,26). Moreover, heritability estimates of depressive symptoms, as measured
with the CES-D, range from 15% to 34% (27–29).
We present the results of a meta-analysis combining genome-wide association results of
depressive symptoms from 17 population-based studies of European ancestry (n = 34,549).
In addition, we sought to replicate our findings in five samples that used instruments other
than the CES-D to quantify depressive symptoms (n = 16,709). Finally, we performed a
combined meta-analysis of all discovery and replication studies that included 51,258
individuals.
Methods and Materials
Discovery Samples
This discovery set included results from 17 population-based studies comprising a total of
34,549 persons of European descent. The following studies collaborating in the Cohorts for
Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (30) in the
United States and Europe were included: the Atherosclerosis Risk In Communities 1 and 2
studies (ARIC1 and ARIC2) (31), the Cardiovascular Health Study (CHS) (32), the
Framingham Heart Study (FHS) (33,34), and the Rotterdam Study I, II, and III (RS-I, RS-II
and RS-III) (35). The following population-based studies joined the discovery analyses: the
Baltimore Long-itudinal Study of Aging (BLSA) (36); The Erasmus Rucphen Family (ERF)
(37) study; the Health, Aging and Body Composition study (Health ABC); the Invecchiare
in Chianti (Aging in the Chianti area; InCHIANTI) (38) study; Helsinki Birth Cohort Study
(HBCS) (39); Multi-Ethnic Study of Atherosclerosis (MESA) (40); Nurses’ Health Study
(NHS) (41); Rush Memory and Aging Project (MAP) (42); Religious Orders Study (ROS)
(43), and SardiNIA study (44). All studies were approved by their local institutional review
boards and all participants provided written informed consent.
Phenotype Definition
Depressive symptoms were measured with the CES-D scale (10-item version [CHS, NHS,
Rush MAP, Rush ROS], 11- item version [ARIC1], or 20-item version [ARIC2, BLSA,
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ERF, FHS, HBCS, Health ABC, InCHIANTI, MESA, RS-I, RS-II, RS-III, SardiNIA]). The
CES-D scale is designed for use in the general population. All three CES-D versions used
here detect the same four latent factors (45): depressed affect, somatic symptoms, positive
affect, and interpersonal problems. Each item is scored from 0 to 3 depending on the
frequency of the symptoms during the past week. A higher score corresponds to more
depressive symptoms. Scores from one examination round per study were used, but CES-D
scores have been shown to be relatively stable over time (23,24). In studies with multiple
CES-D assessments, the round with the largest number of participants (generally the first
examination round) was chosen. Persons with schizophrenia or bipolar disorder were
excluded, based on records, interviews, or medication use (these disorders probably have a
distinct genetic component). In addition, persons with a Mini-Mental State Examination
score < 22, indicative of dementia, were excluded. We included persons with genotype data
and depressive symptom score who were aged 40 years and older.
Adjustment for Use of Antidepressants
In the search for common variants for depressive symptoms in a population-based sample,
persons using antidepressants, who most likely had depression or depressive symptoms,
increase genetic information. We, thus, did not exclude these persons from the analysis, but
we chose to adjust their total depressive symptoms score for medication use. However,
response to antidepressants is highly variable. In addition, information on compliance is
often not available in population-based studies. We therefore used a nonparametric
imputation algorithm to adjust the CES-D score for treatment effect. We made two
assumptions: the CES-D score of a person using antidepressants is a right-censored value,
i.e., the score is lower than the untreated value would be; and persons with a high CES-D
score, on average, responded less to their medication than persons with a lower CES-D
score. We replaced the score of a person on antidepressants with the mean depressive
symptom score of all persons using antidepressants that had the same or a higher depressive
symptom score. This procedure was performed separately for men and women and was
based on an algorithm used for adjustment of blood pressure for persons on antihypertensive
drugs (46). Antidepressant medication was defined by each study separately to account for
differences between countries.
Genotyping and Imputation
Genome-wide genotyping was performed by the individual studies on Illumina (Illumina,
Inc., San Diego, California) or Affymetrix (Affymetrix, Santa Clara, California) platforms.
All studies imputed their genotype data to ~2.5 million single nucleotide polymorphisms
(SNPs) to account for the different genotyping platforms. HapMap release 22 CEU
(HapMap sample comprised of Utah residents with Northern and Western European
ancestry) build 36 was generally used as reference for imputation (two studies used build
35). Genotype and imputation quality control were performed in each study separately.
Genotype and quality control procedures for each study can be found in Table S1 in
Supplement 1.
Data Analysis
A linear regression was performed on total depressive symptom score, adjusted for age and
gender. The distribution of CES-D scores is skewed, but linear regression is fairly robust to
nonnormality. Cardiovascular Health Study and Atherosclerosis Risk In Communities
additionally adjusted for field study site, NHS for disease status, SardiNIA for self-report
versus tester-read and reported answers, and FHS for cohort (offspring, generation 3).
Furthermore, FHS used linear mixed effect models to account for familial correlations. In
the ERF study, kinship matrix was used to correct for relatedness.
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Meta-Analysis
We performed a p value based meta-analysis weighted by sample size. This is a valid
approach to account for the different CES-D versions to measure depressive symptoms and
for the different distributions of depressive symptoms. The meta-analysis test statistic was
computed as follows:
The meta-analysis was performed with METAL (http://www.sph.umich.edu/csg/abecasis/
metal/) (47). The beta (β) of each individual study i was matched to a common coded allele
(the minor allele) for each SNP across all studies. Single nucleotide polymorphisms with a
minor allele frequency less than 2.5% or an observed to expected variance ratio (imputation
quality) less than .30 were excluded on a per study basis. Single nucleotide polymorphisms
for which the total sample size was lower than 5000 were removed from the results.
Genomic control correction was applied to each study’s results.
Replication
Independent top SNPs with a p value < 1 × 10−5 in the discovery meta-analysis were
selected with the clumping function in PLINK (http://pngu.mgh.harvard.edu/purcell/plink/)
(48) (R2 < .05, 500 kilobase [kb]) for replication in five studies that measured depressive
symptoms with other instruments (total n = 16,709). Persons included in the replication
studies were independent from those in the discovery studies. Although replication with
other instruments than the CES-D might introduce some heterogeneity, all instruments
measure depressive symptoms. Further, a positive replication would ensure that our top hits
are not instrument-dependent.
Age, Gene, Environment Susceptibility–Reykjavik Study (AGES) (49), the ARIC 3 study
(31), Monitoring of Trends and Determinants of Cardiovascular Disease/Cooperative Health
Research in the Region of Augsburg F3 and F4 (MONICA/KORA F3 and F4) (50), and the
Study of Health in Pomerania (SHIP) (51,52) measured depressive symptoms with the
Geriatric Depression Scale (GDS), Maastricht Questionnaire, Patient Health Questionnaire
(PHQ-9), and the Beck Depression Inventory-II (BDI-II), respectively. The BDI-II, GDS,
and PHQ-9 aim to screen for depression and are highly correlated (53,54). The BDI-II is
based on the DSM-IV criteria for MDD and comprises 21 items on a scale of 0 to 3 with
higher scores indicating more severe depressive symptoms over the past 2 weeks. The
PHQ-9 is, like the BDI-II, based on the DSM-IV criteria for MDD, but it consists of nine
items on a scale of 0 to 3 to assess depressive symptoms over the past 2 weeks. The GDS
was specifically designed to screen for depression in older adults and comprised 15 items
answered with “yes” or “no.” The Maastricht Questionnaire (21 items), although designed to
measure vital exhaustion, correlates with measures of depressive symptoms (55) and was
previously used to assess depressive symptoms (56,57).
Replication was considered significant if the Bonferroni-corrected p value for testing seven
SNPs was ≤.050 (uncorrected p value ≤ 7.1 × 10−3).
Pathway Analysis
Protein ANalysis THrough Evolutionary Relationships (PANTHER) (58) was used to
identify and classify biological processes among the SNPs associated with p values < 10−4
from the overall meta-analysis (n = 51,258). After SNP selection, SNPs were annotated to
genes and/or flanking genes with the SCAN SNP and CNV Annotation Database (http://
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www.scandb.org). Protein ANalysis THrough Evolutionary Relationships then compares
this gene list to a reference list (Homo Sapiens gene list from the National Center for
Biotechnology Information) using the binomial test. Results were Bonferroni-corrected to
account for multiple testing.
Candidate Gene Search
Altogether, 17 SNPs previously reported to be associated to depression were selected: 1
SNP that has been found genome-wide significantly associated with depressive phenotypes
after replication (7,59), 4 top SNPs from the largest MDD meta-analysis so far (13), and 12
top SNPs from the only published GWAS that studied a depressive trait continuously (21).
Single nucleotide polymorphisms were tested for association in the discovery meta-analysis
(n = 34,549) and in the overall meta-analysis including all studies that measured depressive
symptoms (n = 51,258).
Results
Meta-Analysis of Depressive Symptoms
Table 1 shows the characteristics of the study populations. Mean age in the discovery studies
ranged between 55.9 and 80.8 years. The percentage of women varied between 44.6% and
100%. In line with the population-based design of the studies, median depressive symptoms
scores ranged between 2 and 10 for the CES-D 20-item version. This is well below the
cutoff of 16 at which major depression cases in older adults can be identified with high
specificity and sensitivity (22). The percentage of persons scoring above this cutoff varied
between 4.7% and 27.1%. Distributions of CES-D scores differed between studies and
therefore a Z-score based meta-analysis was used to combine the individual study results.
Antidepressant use ranged from 3.0% to 14.0%. On average, CES-D scores for persons on
antidepressants more than doubled after imputation.
The genomic control inflation factor lambda (λgc) for each study ranged between .997 and
1.024. A meta-analysis of 17 studies (n = 34,549) with depressive symptoms measured by
CES-D was performed (Q-Q and Manhattan plots in Figure S1 in Supplement 1). The total
number of SNPs analyzed was 2,391,896. No association reached the prespecified genome-
wide significance level of 5 × 10−8 for the association with the depressive symptom score.
However, we identified 117 SNPs with a p value < 1 × 10−5, which included seven
independent top SNPs (R2 < .05 in 500 kb, Table 2). The SNP with the lowest p value was
rs8020095 (p = 1.05 × 10−7) and maps to an intronic region of GPHN on chromosome 14.
Of the seven top SNPs, none had a heterogeneity p value (tested by Cochran’s Q) below .05
in the discovery meta-analysis.
We reran the analysis for the independent top SNPs excluding people on antidepressants; p
values of the top SNPs shifted toward one (e.g., rs8020095 p value 1.56 × 10−6, rs161645 p
value 1.71 × 10−3). Adding five points to the total score for people using antidepressants in a
subsample (RS-I, RS-II, RS-III, n = 7925) resulted in the same top SNPs and similar p
values for the top SNPs tested here.
Replication
Table 2 presents the results of the replication analysis and the overall meta-analysis across
discovery sample and replication sample. The mean observed to expected variance ratio for
the seven top SNPs across all cohorts ranged between .91 and .98 (Table S2 in Supplement
1). In the replication sample, an SNP on chromosome 5 showed an association with
depressive symptoms (5q21, rs161645, p = 9.19 × 10−3, Table 2), but this association did not
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reach the predefined threshold for multiple testing (corrected for multiple testing p = .064).
This SNP resides in a gene desert, with the closest gene NUDT12 more than 1000 kb away.
In the overall meta-analysis including discovery and replication samples (n = 51,258), SNP
rs40465 reached genome-wide significance (p = 4.78 × 10−8). This SNP is in high linkage
disequilibrium with SNP rs161645 (R2 = .80). Rs40465 had a p value of 2.58 × 10−6 in the
discovery meta-analysis and a p value of 5.00 × 10−3 in the meta-analysis of replication
studies. An association plot of the 5q21 region is presented in Figure 1.
In contrast, the strength of the associations of the other top SNPs with depressive symptoms
was attenuated, as judged by the p value. All SNPs with a p value < 1 × 10−4 from the
overall meta-analysis (n = 51,258) are presented in Table S3 in Supplement 1.
Pathway Analysis
One hundred four functional genes of the 170 genes that were annotated were mapped to
biological processes. Relevant processes that were overrepresented among top SNPs (p
value < 10−4) of the overall meta-analysis were neurotransmitter secretion (Bonferroni-
corrected p value = 9.84 × 10−3), vitamin transport (Bonferroni-corrected p value = .014),
and synaptic transmission (Bonferroni-corrected p value = .037). A complete list of
biological processes that were significantly overrepresented is presented in Table 3.
Candidate Gene Search
None of the 17 tested candidate genes were replicated in the current study (Table S4 in
Supplement 1). Nine out of 17 associations had the same direction in our overall meta-
analysis as in the published study, and none of the nine was significant (uncorrected for
multiple testing).
Discussion
In this GWAS of depressive symptoms, we combined the results of 17 population-based
studies with 34,549 individuals to find common variants for depressive symptoms. Including
the five replication studies, this effort comprised data from 51,258 independent individuals.
Of the seven SNPs we attempted to replicate, we found suggestive evidence for the observed
association of one SNP in the 5q21 region with depressive symptoms. This region reached
genome-wide significance when tested over all studies (n = 51,258).
Although evidence shows that depression can be well represented by a continuum of
depressive symptoms, we observed a genome-wide significant hit in this large GWAS only
when pooling all studies with depressive symptoms. This difficulty of finding signals is in
line with GWAS of major depression. Nine GWAS of depression, of which the largest
comprised ~6000 MDD cases and ~7000 control subjects, yielded only one genome-wide
significant finding (15).
The approach of studying depression on a continuum has the advantage that not only
information on extremes is used but that all available information is exploited. Van der Sluis
et al. (20) showed that if the phenotypic variation among cases, as well as the variation
among control subjects, is used, this greatly increases the power to detect genetic variants.
However, studying depression along a continuum in population-based studies implies that
many individuals have a low depressive symptoms score and that few persons score high.
Therefore, it remains to be validated whether the results presented here are generalizable to
clinical depression cases. In addition, the CES-D measures current depressive symptoms and
not remitted depressive symptomatology. This introduces false-negatives, but in this
population-based approach in which low depressive symptomatology is overrepresented, the
Hek et al. Page 8
Biol Psychiatry. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
resulting bias would be conservative. Furthermore, the distribution of depressive symptoms
differed between cohorts. We therefore performed a p value based meta-analysis, which is a
valid approach, but has the consequence that we cannot draw conclusions on effect sizes.
Differences in depressive symptoms distribution do not impact on the validity of the
findings. People with high depressive symptoms are more likely to carry risk variants, but
this should not depend on the number of people with a high score. Furthermore, the
distribution of I2, a measure of heterogeneity (60), of the results combining all samples did
not differ from the distribution of I2 of the results when samples with low or high depression
prevalence were meta-analyzed separately. No excess heterogeneity was observed, which
suggests that depressive symptoms can be analyzed linearly. However, some genetic main
effects may be more detectable in very homogeneous populations. Observed differences in
distributions of depressive symptoms may have resulted from environmental factors, and if
these, in turn, interact with specific genetic variants, only very homogeneous studies could
also detect a genetic main effect.
Environmental factors, like education level, differed among cohorts. In observational
research, one would have controlled for such possible confounders. In genetic studies,
confounding by environmental factors is unlikely to occur (61), but controlling for
environmental factors can also be done to increase precision, i.e., reduce the variance in
depressive symptoms (62). However, environmental factors explain very little variance in
depressive symptoms. Therefore, the benefit of performing additional controlled analyses
will be negligible and offset by running several models with the risk of multiple testing.
In the current study, depressive symptom scores for people using antidepressants were
imputed to take into account the high variability in response to antidepressants. In an
analysis of depressive symptoms, people on antidepressants, who most likely had depression
or depressive symptoms, are particularly informative. Therefore, excluding this group a
priori may have changed the results. In a subsample, the imputation algorithm used in the
current study yielded similar results as adding an arbitrary score of five points to the
depressive symptom scores of people using antidepressants.
This study was performed in older adults. Cerebrovascular burden and cognitive
impairment, which have a relatively high prevalence in old age, are known to be associated
with depressive symptoms. In addition, while a high CES-D score indicates depressive
symptoms, it can also be suggestive of, for example, anxiety (63). In other words, the level
of depressive symptoms is a clinically heterogeneous phenotype. However, the genetic
background of clinically heterogeneous phenotypes like anxiety and depression may be
more uniform than the clinical presentation suggests (64). In addition, while nongenetic
determinants of depression may differ with age, genetic determinants were shown to be
stable at different ages (65,66). Therefore, the results presented here are presumably
generalizable to younger populations.
We combined results from studies that measured depressive symptoms with instruments
other than the CES-D to replicate the association between depressive symptoms and seven
independent top SNPs. In an overall meta-analysis, we tested whether any variation
introduced by different instruments was offset by the increased power. In the replication
effort, one SNP (5q21 region) reached a p value below .05 but did not pass this threshold
when controlling for multiple testing. Another SNP in the 5q21 region, however, reached
genome-wide significance when the association across discovery and replication studies was
tested (n = 51,258). The 5q21 region resides in a gene desert with the closest gene,
NUDT12, lying more than 1000 kb away. NUDT12 has not been previously implicated in
psychiatric disorders.
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Although we observed suggestive association of the 5q21 region with depressive symptoms,
genome-wide significance was observed only after pooling the results of the discovery and
replication studies. Also, we could not replicate associations with candidate genes that
previously have been reported to be associated with depression. Several explanations are
plausible.
A first explanation for these observations is that the top SNPs identified in this study are
false-positive findings. However, the discovery set was large and although we did not find
any genome-wide significant hits, true hits are expected to be found among the top findings.
A pathway analysis on the results of the overall meta-analysis showed that biological
processes that play a role in depression were overrepresented among our top hits.
Second, the replication sample was smaller than the discovery sample and may be
underpowered to detect true effects with moderate effect sizes, which might have been
overestimated in the discovery analysis (winner’s curse). Indeed, we found suggestive
evidence of association for only one of seven SNPs, but the direction of association was
compatible for five out of seven SNPs.
Third, lack of replication might be related to heterogeneity of the replication phenotype. In
the replication approach, we combined the results of studies that measured depressive
symptoms with different instruments. Instruments were also administered at different time
points across studies. However, the instruments have been reported to be highly correlated
(correlations between .77 and .86) and relatively stable genetic determinants over the life
span were observed in an Australian Twin study (53,54,65,67,68).
Several other factors can hinder the search for common variants associated with depressive
symptoms. Population stratification, for example, can result in false-positive findings. To
avoid population stratification, only individuals from European descent were included.
Including only individuals from European descent also minimized measurement error
caused by cultural differences in responses to the CES-D (69). Other possible explanations
are the presence of genetic heterogeneity (70), gene-gene interactions (71), and gene-
environment interactions. The interaction between candidate genes and life events has been
repeatedly studied for depression (72). However, to study this phenomenon in a genome-
wide approach requires much larger data sets (13). In addition, it is suggested that the gain
of gene-environment interaction studies over studies of main effects for complex diseases
like depression is minimal (73). The study described here focused on common genetic
variation, but rare variants or copy number variations not tagged by SNPs might play a role
in depression (74,75). Using a larger reference panel, like the haplotypes generated by the
1000 Genomes Project, would have improved the yield of rare variants. Harmonizing
imputation reference and imputation tools might have further increased the power of the
study to detect associations. Also, not single SNPs, but many SNPs collectively, each with a
very small effect, may affect the susceptibility for depressive symptoms (66).
In conclusion, the efforts of a large collaboration to identify common variants associated
with depressive symptoms yielded no genome-wide significant hit in the discovery sample.
In the replication approach, we found suggestive evidence for a SNP in the 5q21 region.
When analyzing the discovery and replication samples, one genome-wide significant hit in
this region was observed. Further investigation of the 5q21 region is necessary to verify the
association with depressive symptoms and to pinpoint the possible functional variant. Such a
future study of depressive symptoms could analyze this phenotype stratified by gender and
incorporate longitudinal information with repeated measures of depressive symptoms to
provide more power to our search for potential candidate genes.
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Figure 1.
Association results in the 5q21 region. Summary of the association of single nucleotide
polymorphisms (SNPs) on chromosome 5 (base 103,500,000 to 104,500,000) with
depressive symptoms from the overall meta-analysis (n = 51,258). The SNP with the
strongest association (rs40465) is highlighted in blue and its corresponding p value is given.
Other SNPs are colored according to their degree of linkage disequilibrium (LD) with
rs40465, ranging from high LD (orange, R2 .5–1.0) to low LD (white, R2 < .2). cM,
centimorgan; kb, kilobase; Mb, megabase.
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Table 3
Pathway Analysis
Biological Process NCBI Observed Expected Over/
Under
Adjusted
p Valuea
Neurotransmitter
 Secretion
346 6 1.81 + 9.84e-03
Vitamin Transport 95 3 .50 + .014
Protein Metabolic
 Process
3240 26 16.92 + .015
Synaptic Transmission 594 7 3.10 + .037
Transport 2857 22 14.92 + .038
Vesicle-Mediated
 Transport
1160 11 6.06 + .040
Cation Transport 621 7 3.24 + .045
Cell-Cell Signaling 1331 12 6.95 + .045
Protein Transport 1646 14 8.60 + .048
Intracellular Protein
 Transport
1646 14 8.60 + .048
Enrichment of biological processes among the top results (overall meta-analysis p value < 10−4) was statistically tested with a binomial test.
NCBI: number of genes in a biological process (reference). Observed: number of genes that belong to a biological process among the GWAS
results. Expected: expected number of genes that belong to a biological process in the GWAS results. Over/under: overrepresentation or
underrepresentation of the genes in the results.
GWAS, genome-wide association studies; NCBI, National Center for Biotechnology Information.
aA Bonferroni-correction was applied to correct for multiple testing.
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